🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 29337E102 (prev. 45249V107 )
- Market Cap
- Mid Cap
- IPO
- 3/12/2020 · $16.00/share
- Previous Symbol
- IMRA (changed 2/23/2023)
- Previous Name
- IMARA Inc.
Business: Enliven Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing small molecule kinase inhibitors to address existing and emerging unmet needs in oncology.
Notes: Oct. 13, 2022 -- Enliven Therapeutics, Inc. (Enliven), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. (Nasdaq: IMRA) (Imara) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Enliven’s pipeline of precision oncology product candidates.
Company Contact
- CEO
- Sam Kintz
- CFO
- Ben Hohl
- Headquarters
- 6200 Lookout Road, Boulder, CO 80301
- Phone
- 720-647-8519
- Investor Relations
- Michael Gray · 857-320-4636 · ir@enliventherapeutics.com